October 20, 2016
Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD)
-- GS-4997 Demonstrates Anti-Fibrotic Activity in Open-Label Phase 2 NASH Study; Data Support Plans to Advance GS-4997 into Phase 3 Clinical Trials --
Endpoint (Week 24)
GS-4997 18 mg
GS-4997 6 mg
|Fibrosis Improvement ≥1 Stage from Baseline*||43% (n=13/30)||30% (n=8/27)||20% (n=2/10)|
|Progression to Cirrhosis||
*Fibrosis staged according to the NASH Clinical Research Network (CRN) classification by a central pathologist blinded to treatment group.
Overall, GS-4997 was well tolerated with no dose-related increase in the incidence of treatment-emergent adverse events or serious adverse events. The most common adverse events were headache, nausea and sinusitis.
“We are committed to advancing our pipeline of investigational molecules that separately target metabolic dysfunction, inflammation and/or fibrosis associated with NASH,” said
Separately, a Phase 2 study of GS-4997 in PAH did not achieve its primary endpoint and a Phase 2 study in DKD did not achieve its primary endpoint based on a preliminary analysis. Due to insufficient evidence of efficacy, Gilead has decided not to pursue Phase 3 studies of GS-4997 in PAH or DKD at this time. Data from these studies will be submitted for presentation at upcoming scientific conferences.
About the GS-4997 Phase 2 Studies
Study GS-US-384-1497 was a Phase 2, randomized, open-label clinical trial designed to evaluate the safety, tolerability and efficacy of GS-4997 alone or in combination with simtuzumab in 72 patients with NASH and fibrosis stages F2-F3. Eligible patients were randomized (2:2:1:1:1) to receive GS-4997 6 mg (n=20), GS-4997 18 mg (n=22), GS-4997 6 mg plus simtuzumab 125 mg (n=10), GS-4997 18 mg plus simtuzumab 125 mg (n=10) or simtuzumab 125 mg alone (n=10) for 24 weeks. GS-4997 was administered orally once daily and simtuzumab was administered via weekly subcutaneous injection. Since no differences were observed between combination and monotherapy, data in the table above are presented by GS-4997 treatment group only.
Study GS-US-223-1015 was a Phase 2 double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of GS-4997 in 334 patients with type 2 diabetes mellitus and Stage 3 or 4 renal impairment and albuminuria. Eligible patients were randomized (1:1:1:1) to receive GS-4997 doses of 2 mg (n=81), 6 mg (n=84), 18 mg (n=84) or matching placebo (n=85) once daily on top of DKD background therapy for 48 weeks. The primary endpoint was change in estimated glomerular filtration rate (eGFR) from baseline at Week 48.
ARROW was a Phase 2, dose-ranging, randomized, double-blind, placebo-controlled study designed to determine the safety, efficacy and tolerability of three doses of GS-4997 in 151 patients with PAH (
Further information about these studies can be found at www.clinicaltrials.gov.
GS-4997 and simtuzumab are investigational products and have not been determined to be safe or efficacious.
GS-4997 is an investigational small molecule inhibitor of apoptosis signal-regulating kinase 1 (ASK1), a protein that promotes inflammation, apoptosis (cell death) and fibrosis in settings of oxidative stress. Oxidative stress normally occurs at low levels in healthy states, but can be increased in many pathological conditions such as NASH.
About Gilead’s Clinical Programs in NASH
Gilead is advancing a pipeline of novel investigational therapies for the treatment of NASH with advanced fibrosis. Gilead is currently planning or conducting Phase 2 and Phase 3 clinical trials evaluating single-agent and combination therapy approaches against multiple core pathways associated with NASH – metabolic dysfunction, inflammation and fibrosis.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City,
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate its Phase 3 clinical trial program evaluating GS-4997 in patients with NASH in the currently anticipated timelines or at all. In addition, there is the possibility of unfavorable results from further clinical trials involving GS-4997, including in patients with NASH. Further, it is possible that Gilead may make a strategic decision to discontinue development of GS-4997 if, for example, Gilead believes commercialization will be difficult relative to other opportunities in its pipeline. As a result, GS-4997 may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended
For more information on
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Nathan Kaiser, 650-522-1853